RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial

European Journal of Cancer

Volumn 50, Issue 8, 2014, Pages 1430-1436

  Sclafani, F ^a   Gonzalez, D ^a   Cunningham, D ^a   Hulkki Wilson, S ^a   Peckitt, C ^a   Giralt, J ^b   Glimelius, B ^c   Rosello Keranen S ^d   Wotherspoon, A ^a   Brown, G ^a   Tait, D ^a   Oates, J ^a   Chau, I ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

BRAF; Cetuximab; KRAS; Neoadjuvant chemotherapy; NRAS; RAS; Rectal cancer

Indexed keywords

B RAF KINASE; CAPECITABINE; CETUXIMAB; K RAS PROTEIN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; ONCOGENE N RAS; ONCOGENE RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; RETROSPECTIVE STUDY; TREATMENT RESPONSE; WILD TYPE;

BRAF; CETUXIMAB; KRAS; NEOADJUVANT CHEMOTHERAPY; NRAS; RAS; RECTAL CANCER;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; RAS PROTEINS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84898863809     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.02.002     Document Type: Article

References (27)

1. N.I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clin Cancer Res 1 1995 1311 1318
2. K.A. Foon, X.D. Yang, and L.M. Weiner et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody Int J Radiat Oncol Biol Phys 58 2004 984 990 (Pubitemid 38221160)
3. D. Cunningham, Y. Humblet, and S. Siena et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345 (Pubitemid 38944402)
4. D.J. Jonker, C.J. O'Callaghan, and C.S. Karapetis et al. Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2007 2040 2048 (Pubitemid 350106711)
5. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
6. E. Van Cutsem, M. Peeters, and S. Siena et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664 (Pubitemid 46797944)
7. R.G. Amado, M. Wolf, and M. Peeters et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
8. E. Van Cutsem, C.H. Kohne, and E. Hitre et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
9. C. Bokemeyer, I. Bondarenko, and A. Makhson et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
10. C. Bokemeyer, E. Van Cutsem, and P. Rougier et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur J Cancer 48 2012 1466 1475
11. J.-Y. Douillard, S. Siena, and J. Cassidy et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
12. M. Peeters, T.J. Price, and A. Cervantes et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 2010 4706 4713
13. W. De Roock, B. Claes, and D. Bernasconi et al. Effect of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
14. W. De Roock, V. De Vriendt, N. Normanno, F. Ciardiello, and S. Tejpar KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer Lancet Oncol 12 2011 594 603
15. F. Di Nicolantonio, M. Martini, and F. Molinari et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
16. S. Siena, A. Sartore-Bianchi, and F. Di Nicolantonio et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 101 2009 1308 1324
17. F. Sclafani, G. Gullo, K. Sheahan, and J. Crown BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications Crit Rev Oncol Hematol 87 2013 55 68
18. J. Tol, I.D. Nagtegaal, and C.J. Punt BRAF mutation in metastatic colorectal cancer N Engl J Med 361 2009 98 99
19. E. Van Cutsem, C.H. Köhne, and I. Láng et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011 2011 2019
20. M. Peeters, K.S. Oliner, and A. Parker et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer Clin Cancer Res 19 2012 1902 1912
21. J.-Y. Douillard, K.S. Oliner, and S. Siena et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 2013 1023 1034
22. S.R. Alberts, D.J. Sargent, and S. Nair et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer JAMA 307 2012 1383 1393
23. A. Dewdney, D. Cunningham, and J. Tabernero et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C) J Clin Oncol 30 2012 1620 1627
24. Stintzing S, Jung A, Rossius L, et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. European Cancer Congress (ECCO-ESMO-ESTRO) 2013; Abstract LBA17.
25. Sclafani F, Cunningham D, Tabernero J, et al. Updated survival analysis of EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab in MRI-defined high risk rectal cancer patients. European Cancer Congress (ECCO-ESMO-ESTRO) 2013; Abstract 2168.
26. N.H. Segal, and L.B. Saltz Antitumor activity in metastatic disease does not predict efficacy in the adjuvant setting JAMA 307 2012 431 1432
27. Sclafani F, Gonzalez de Castro D, Cunningham D, et al. TP53 status may predict benefit from cetuximab in high-risk, locally advanced rectal cancer: 5-year results of the EXPERT-C trial. European Cancer Congress (ECCO-ESMO-ESTRO) 2013; Abstract LBA7.